Elonva is a hormonal medicine used in women who are undergoing fertility treatment to stimulate the development of more than one mature egg at a time in the ovaries. It is used together with a gonadotrophin-releasing hormone (GnRH) antagonist (another type of medicine used in fertility treatments). Elonva combined with another hormonal medicine called human chorionic gonadotropin (hCG) is also used to treat adolescent boys aged 14 years and older who have delayed or absent puberty due to hypogonadotropic hypogonadism. In adolescent males with this condition, production of the hormones that stimulate testicular development is inadequate. Therefore, the testes remain small and produce little or no testosterone. This results in delayed or absent pubertal characteristics, and no sperm production resulting in problems with fertility. Elonva contains the active substance corifollitropin alfa.
Therapeutic Indication
### Therapeutic indication Controlled Ovarian Stimulation (COS) in combination with a GnRH antagonist for the development of multiple follicles in women participating in an Assisted Reproductive Technology (ART) program. Elonva is indicated for the treatment of adolescent males (14 to less than 18 years and older) with hypogonadotropic hypogonadism, in combination with human Chorionic Gonadotropin (hCG).
Therapeutic Area (MeSH)
ATC Code
G03GA09
ATC Item
corifollitropin alfa
Pharmacotherapeutic Group
Sex hormones and modulators of the genital system
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| corifollitropin alfa | N/A | Corifollitropin alfa |
EMA Name
Elonva
Medicine Name
Elonva
Aliases
N/ANo risk management plan link.
